WO2010120112A2 - Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof - Google Patents
Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof Download PDFInfo
- Publication number
- WO2010120112A2 WO2010120112A2 PCT/KR2010/002306 KR2010002306W WO2010120112A2 WO 2010120112 A2 WO2010120112 A2 WO 2010120112A2 KR 2010002306 W KR2010002306 W KR 2010002306W WO 2010120112 A2 WO2010120112 A2 WO 2010120112A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- benzyl
- methyl
- indol
- dioxo
- ylmethyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 32
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 20
- 150000001875 compounds Chemical class 0.000 title claims description 100
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims abstract description 23
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims abstract description 18
- 125000000217 alkyl group Chemical group 0.000 claims description 41
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 39
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 37
- 238000006243 chemical reaction Methods 0.000 claims description 29
- 239000000126 substance Substances 0.000 claims description 24
- 125000003118 aryl group Chemical group 0.000 claims description 16
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- XQVZDADGTFJAFM-UHFFFAOYSA-N Indole-7-carboxaldehyde Chemical compound O=CC1=CC=CC2=C1NC=C2 XQVZDADGTFJAFM-UHFFFAOYSA-N 0.000 claims description 12
- 125000000304 alkynyl group Chemical group 0.000 claims description 12
- 125000004122 cyclic group Chemical group 0.000 claims description 9
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 8
- 125000002252 acyl group Chemical group 0.000 claims description 8
- 235000019253 formic acid Nutrition 0.000 claims description 8
- 125000003107 substituted aryl group Chemical group 0.000 claims description 8
- 239000000543 intermediate Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- HJKLEAOXCZIMPI-UHFFFAOYSA-N 2,2-diethoxyethanamine Chemical group CCOC(CN)OCC HJKLEAOXCZIMPI-UHFFFAOYSA-N 0.000 claims description 6
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 claims description 6
- 239000007806 chemical reaction intermediate Substances 0.000 claims description 6
- YDNLNVZZTACNJX-UHFFFAOYSA-N isocyanatomethylbenzene Chemical compound O=C=NCC1=CC=CC=C1 YDNLNVZZTACNJX-UHFFFAOYSA-N 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 5
- 229910018828 PO3H2 Inorganic materials 0.000 claims description 5
- 230000002862 amidating effect Effects 0.000 claims description 5
- 238000005863 Friedel-Crafts acylation reaction Methods 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- GETVBTMFGVOGRW-UHFFFAOYSA-N ethyl 2-hydrazinylacetate Chemical compound CCOC(=O)CNN GETVBTMFGVOGRW-UHFFFAOYSA-N 0.000 claims description 4
- 230000000865 phosphorylative effect Effects 0.000 claims description 3
- JPYQFYIEOUVJDU-UHFFFAOYSA-N beclamide Chemical compound ClCCC(=O)NCC1=CC=CC=C1 JPYQFYIEOUVJDU-UHFFFAOYSA-N 0.000 claims 13
- 239000002253 acid Substances 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 abstract description 20
- 230000002441 reversible effect Effects 0.000 abstract description 10
- VPABNAIRKXOCDU-UHFFFAOYSA-N 1h-pyrazino[2,3-d]triazin-4-one Chemical compound C1=CN=C2C(=O)NN=NC2=N1 VPABNAIRKXOCDU-UHFFFAOYSA-N 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 78
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 42
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 33
- 230000015572 biosynthetic process Effects 0.000 description 23
- 238000003786 synthesis reaction Methods 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 239000000651 prodrug Substances 0.000 description 22
- 229940002612 prodrug Drugs 0.000 description 22
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 21
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
- 239000010410 layer Substances 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 239000000203 mixture Substances 0.000 description 18
- 239000012153 distilled water Substances 0.000 description 16
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- 229940093499 ethyl acetate Drugs 0.000 description 14
- 235000019439 ethyl acetate Nutrition 0.000 description 14
- 239000012044 organic layer Substances 0.000 description 14
- 238000003756 stirring Methods 0.000 description 14
- 238000012360 testing method Methods 0.000 description 13
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 12
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 12
- -1 cyclic hydrocarbon radical Chemical class 0.000 description 12
- 238000000926 separation method Methods 0.000 description 12
- 229910052938 sodium sulfate Inorganic materials 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- 206010048610 Cardiotoxicity Diseases 0.000 description 10
- 231100000259 cardiotoxicity Toxicity 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 125000003342 alkenyl group Chemical group 0.000 description 9
- 229960003010 sodium sulfate Drugs 0.000 description 9
- 235000011152 sodium sulphate Nutrition 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- 101001047090 Homo sapiens Potassium voltage-gated channel subfamily H member 2 Proteins 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 229910019142 PO4 Inorganic materials 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 235000021317 phosphate Nutrition 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- 125000000524 functional group Chemical group 0.000 description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 238000010253 intravenous injection Methods 0.000 description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000010452 phosphate Substances 0.000 description 7
- 230000004614 tumor growth Effects 0.000 description 7
- 102100022807 Potassium voltage-gated channel subfamily H member 2 Human genes 0.000 description 6
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229910014585 C2-Ce Inorganic materials 0.000 description 5
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 230000003278 mimic effect Effects 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 229910001415 sodium ion Inorganic materials 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 230000000975 bioactive effect Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 3
- 239000007832 Na2SO4 Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 229910019213 POCl3 Inorganic materials 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000004156 Wnt signaling pathway Effects 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 150000005840 aryl radicals Chemical class 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 150000002431 hydrogen Chemical group 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- CMPQUABWPXYYSH-UHFFFAOYSA-N phenyl phosphate Chemical compound OP(O)(=O)OC1=CC=CC=C1 CMPQUABWPXYYSH-UHFFFAOYSA-N 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 125000004436 sodium atom Chemical group 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- JAUKCFULLJFBFN-VWLOTQADSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[4-[(2-methylpropan-2-yl)oxy]phenyl]propanoic acid Chemical compound C1=CC(OC(C)(C)C)=CC=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 JAUKCFULLJFBFN-VWLOTQADSA-N 0.000 description 1
- YKVBQSGNGCKQSV-SFHVURJKSA-N (2s)-3-[4-[(2-methylpropan-2-yl)oxy]phenyl]-2-(phenylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC(OC(C)(C)C)=CC=C1C[C@@H](C(O)=O)NC(=O)OCC1=CC=CC=C1 YKVBQSGNGCKQSV-SFHVURJKSA-N 0.000 description 1
- OBQRODBYVNIZJU-UHFFFAOYSA-N (4-acetylphenyl)boronic acid Chemical compound CC(=O)C1=CC=C(B(O)O)C=C1 OBQRODBYVNIZJU-UHFFFAOYSA-N 0.000 description 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 1
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- 0 *c(c1c2c(CN(CC(N3C4Cc(cc5)ccc5O*)N(C(NCc5ccccc5)=O)N(CC=C)CC3=O)C4=O)ccc1)c[n]2I#* Chemical compound *c(c1c2c(CN(CC(N3C4Cc(cc5)ccc5O*)N(C(NCc5ccccc5)=O)N(CC=C)CC3=O)C4=O)ccc1)c[n]2I#* 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- SFHYNDMGZXWXBU-LIMNOBDPSA-N 6-amino-2-[[(e)-(3-formylphenyl)methylideneamino]carbamoylamino]-1,3-dioxobenzo[de]isoquinoline-5,8-disulfonic acid Chemical compound O=C1C(C2=3)=CC(S(O)(=O)=O)=CC=3C(N)=C(S(O)(=O)=O)C=C2C(=O)N1NC(=O)N\N=C\C1=CC=CC(C=O)=C1 SFHYNDMGZXWXBU-LIMNOBDPSA-N 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- FTEDXVNDVHYDQW-UHFFFAOYSA-N BAPTA Chemical compound OC(=O)CN(CC(O)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(O)=O)CC(O)=O FTEDXVNDVHYDQW-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- ASMQGLCHMVWBQR-UHFFFAOYSA-N Diphenyl phosphate Chemical compound C=1C=CC=CC=1OP(=O)(O)OC1=CC=CC=C1 ASMQGLCHMVWBQR-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- NSGDYZCDUPSTQT-UHFFFAOYSA-N N-[5-bromo-1-[(4-fluorophenyl)methyl]-4-methyl-2-oxopyridin-3-yl]cycloheptanecarboxamide Chemical compound Cc1c(Br)cn(Cc2ccc(F)cc2)c(=O)c1NC(=O)C1CCCCCC1 NSGDYZCDUPSTQT-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229940073584 methylene chloride Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000010583 slow cooling Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65611—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system (X = CH2, O, S, NH) optionally with an additional double bond and/or substituents, e.g. penicillins and analogs
Definitions
- the present invention relates to novel compounds of reverse-turn mimetics, a method for manufacturing the same, and the use thereof in the treatment of diseases, such as acute myeloid leukemia.
- R 3 is a C 1 -Ce alkyl group, a C 2 -C 6 alkenyl , or a C 2 -C6 alkynyl group;
- Rb is an aryl group, a substituted aryl group, or - wherein Rg is a C 1 -Ce alkyl group, a C 2 -C6 alkenyl group, or a C2-C6 alkynyl group; -PO 3 2 T 2 + , -PO 3 2 Hg 2+ , -PO 3 2 Xa 2+ ,
- the substituted aryl may be acyl-substituted aryl (as defined herein).
- R 3 is a C 1 -Q alkyl group or a C2-C5 alkenyl group;
- Rp is -H, - PO 3 H 2 , -HPO 3 " Na + , or -PO 3 2 ⁇ a 2 + .
- Ra is methyl; Rb is - C(O)R 6 wherein R 6 is C 1 -C 6 alkyl; and Rp is -PO 3 H 2 , -HPO 3 " Na + , or -PO 3 2 ⁇ a 2 + .
- the present disclosure provides a pharmaceutical composition comprising a compound provided herein and a pharmaceutical acceptable excipient.
- the present disclosure provides a method for treating acute myeloid leukemia (AML) comprising administering to a patient having AML an effective amount of the compound or composition provided herein.
- the method comprises injecting an effective amount of the compound or composition to a patient having AML.
- the present disclosure provides a method for manufacturing the compound provided herein, comprising the following sequential steps: (a) introducing an acyl group into indole-7-carbaldehyde through Friedel- Crafts Acylation to provide 3-acyl-indole-7-carbaldehyde; (b) introducing an alkyl group and an aminoacetal group to 3-acyl-indole-7-carbaldehyde to provide a l-alkyl-3-acyl-indole derivative; (c) amidating the l-alkyl-3-acyl-indole derivative with stereoselectivity Cbz-Tyrosine-OtBu and 2-(l-allyl-4- benzylsemicarbazido)acetic acid to provide a reaction intermediate; (d) cyclizing the reaction intermediate in the presence of formic acid to provide a cyclic intermediate; and (e) phosphorylating the cyclic intermediate to provide a compound of Chemical Formula (I).
- 2-(l-al lyl-4- benzylsemicarbazido)acetic acid is synthesized by the following sequential steps: (1) adding TEA (triethylamine) to an ethylhydrazinoacetate solution to provide a reaction solution; (2) adding allyl bromide to the reaction solution; and (3) adding benzyl isocyanate. In certain further embodiments, allyl bromide and benzyl isocyanate are added in a dropwise manner.
- TEA triethylamine
- allyl bromide and benzyl isocyanate are added in a dropwise manner.
- the present disclosure provides a method for preparing a compound of Chemical Formula (I), comprising: (a) converting indole-
- Rb is an aryl group, a substituted aryl group, or -C(O)Re, wherein Re is a C 1 -Ce alkyl group, a C2-C6 alkenyl
- Ra i s a C 1 -Ce alkyl group, a C 2 -C 6 alkenyl , or a C 2 -C 6
- Rp is -PQjH 2 , -HPO 3 " Na + , -PO 3 2 IJa 2+ , -PO 3 2 K 2+ , -PO 3 2 Ig 2+ , -PO 3 2 Xa 2+ .
- R 3 is methyl
- Rb is -C(O)R e
- arid R e is methyl or cyclopropyl.
- novel reverse turn mimetics according to the present invention are observed to effectively inhibit the in vitro growth of AML cancer cells. Also, they are observed in testing of mice models of acute myeloid leukemia to effectively inhibit the growth of tumors.
- the leaving group (Rp), also referred to as the prodrug-functional group is separated, the compounds of Chemical Formula I turn into active forms.
- these active forms are difficult to prepare into an aqueous solution due to their poor solubility in water.
- the compounds of Chemical Formula I in accordance with the present invention are of high solubility and of high stability and are easy to be prepared as a preparation for injection.
- the compounds of the present invention have excellent pharmaceutical efficacy. This seems to be attributable to the fast conversion of the compounds into their active forms just after intravenous injection, and thereby an increase in initial drug concentration. In this manner, the speed with which the prodrug compounds turn into active forms has influence on the medicinal efficacy thereof, so that it is important to choose prodrug-functional groups which allow optimal effects.
- the prodrug functional groups are in the form of phosphate because the phosphate prodrugs are converted faster in vivo into active forms than the other prodrugs having other functional groups.
- prodrug-functional groups are in the form of sodium salts, they are easy to prepare and have high solubility in water. In addition, they are highly stable during storage at room temperature.
- a suitable injection composition is known to range in pH from 4 to 9, and preferably has a pH that is close to that of human blood, 7.4.
- a composition which is strongly acidic or strongly basic is not preferred as a composition for injection.
- the final prodrugs of the present invention may be in the form of monosodium or disodium phosphate depending on the amount of sodium hydroxide. These compounds are advantageous for manufacturing a composition having pH values suitable for injection. Further, the manufacturing method according to the present invention allows the production of not only compounds of Chemical Formula I, but also reverse turn mimetics thereof on an industrial scale.
- Figure 1 is a graph showing a correlation between the changes in pH and the potential conducted during the final step of the method for manufacturing the compound, in which 0.5 N NaOH is added dropwise to 4-(((6S,9aS)-l- (benzylcarbamoyl )-8-((3-acetyl-l-methyl-lH-indol-7-yl )methyl )-2-al lyl-octahydro- 4,7-dioxo-lH-pyrazino[2,l-c] [l,2,4]triazin-6-yl)methyl)phenyl dihydrogen phosphate (Compound P2).
- the horizontal axis represents the added amounts of NaOH.
- the first and second points of inflection correspond to the start of the production of monosodium and disodium, respectively.
- one embodiment provides novel reverse turn mimetics, represented by the following Chemical Formula 1, which are useful as therapeutic agents for cancer, in particular for acute myeloid leukemia.
- Chemical Formula 1 wherein
- Rp may be any of the conventional functional groups which are available in prodrugs.
- the functional groups include phosphate, carboxy, and C 1 - C 6 alkyamino, and acylamino, such as -PO 3 H 2 , -HPO 3 " Na + , -PO 3 2- Na 2 + , -PO 3 2 V, -PO 3 2"
- Rp R 0 and Ra are independently H, Na, Mg, Ca or K.
- both of R 0 and Rd are H or Na, or one of them is Na while the other is H.
- Rp may also be - H, the resulting chemical structure in an active form of the corresponding prodrug as the prodrug functional group is removed.
- Ra is an alkyl group, an alkenyl group, or an alkynyl group! preferably a Ci-Ce alkyl group, a C 2 -Ce alkenyl, or a C 2 -Ce alkynyl group! and more preferably a C1-C5 alkyl group.
- Rb is an aryl group, a substituted aryl group, or - R ⁇ is a C 1 -Q alkyl group, a C 2 -Ce alkenyl group, or a C 2 -Ce alkynyl, and the substituted aryl group is a acyl-substituted aryl group and preferably aryl- substituted phenyl.
- alkyl or “alkyl group” is intended to include linear, branched or cyclic hydrocarbon radical comprising carbon and hydrogen atoms, wherein the carbon atoms are linked together by single bonds. In some embodiment, alkyl contains up to 20 carbons.
- an alkyl may comprise one to six carbon atoms and be represented by "Ci-Ce alkyl.”
- An alkyl is attached to the rest of the molecule by a single bond.
- alkyls include, without limitation, methyl, ethyl, /rpropyl, 1-methylethyl (/s ⁇ -propyl), /rbutyl , /rpentyl , /rhexyl, 1,1-dimethylethyl (Hxityl), 2,2-dimethylpropyl (neo-pentyl ) , 3-methylhexyl , 2-methylhexyl , and the like.
- An alkyl may also be a monocyclic or bicyclic hydrocarbon ring radical, which may include fused or bridged ring systems.
- a cyclic alkyl is also referred to as "cycloalkyl .”
- a cycloalkyl may comprise three to six carbon atoms and be represented by "C 3 -6cycloalkyl.”
- monocyclic cycloalkyl radicals include, e.g. , cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl .
- alkenyl or “alkenyl group” refers to linear, branched or cyclic hydrocarbon radical comprising carbon and hydrogen atoms, wherein at least two carbon atoms are linked by a double bond.
- alkyl contains up to 20 carbons.
- an alkenyl may comprise two to six carbon atoms and be represented by "C 2 -Ce alkyl.”
- An alkenyl is attached to the rest of the molecule by a single or double bond. Examples of alkenyls include, without limitation, ethenyl, allyl, butenyl and the like.
- Alkynyl or “alkynyl group” refers to linear, branched or cyclic hydrocarbon radical comprising carbon and hydrogen atoms, wherein at least two carbon atoms are linked by a triple bond.
- alkyl contains up to 20 carbons.
- an alkynyl may comprise two to six carbon atoms and be represented by "C 2 -Q alkynyl.”
- An alkynyl is attached to the rest of the molecule by a single bond. Examples of alkynyls include, without limitation, ethynyl , 1-propynyl, or 2-propynyl and the like. Unless stated otherwise specifically in the specification, the term
- alkyl is meant to include an alkyl having solely carbon and hydrogen atoms as well as “substituted alkyl,” which refers to an alkyl radical in which one or more hydrogen atoms are replaced by one or more substituents independently selected from: acyl , alkoxy, aryl , cyano, cycloalkyl, halo, hydroxyl, nitro, -CC(O)-R 11 , -N(R U ) 2 , -C(O)OR 11 , -C(O)N(R U ) 2 , -N(R 11 X(O)OR 11 , -N(R 11 X(O)R 11 , -N(R u )S(O) t R u (where t is 1 or 2), -S(O) 1 OR 11 (where t is 1 or 2), -S(O)pR u (where p is 0, 1 or 2), and -S(O) t N(
- Alkoxy refers to a radical represented by the formula alkyl-0-, wherein alkyl is as defined herein. The alkyl portion can be further substituted by one or more halogen. An alkoxy may also be represented by the number of the carbons in the alkyl group, for example, Ci-ealkoxy or d-aalkoxy.
- Acyl refers to a radical represented by the formula R 12 C(O)-, wherein R 12 is alkyl or aryl as defined herein. The alkyl or aryl can be optionally substituted with the substituents as described for an alkyl or an aryl group, respectively.
- acyl groups include, without limitation, methylacyl ⁇ i.e., acetyl), phenylacyl, cyclopropylacyl, and the like.
- Aryl refers to a radical derived from an aromatic monocyclic or bicyclic ring system by removing a hydrogen atom from a ring carbon atom.
- the aromatic monocyclic or bicyclic hydrocarbon ring system comprises six to twelve carbon atoms ⁇ i.e. , Ce- ⁇ aryl), wherein at least one of the rings in the ring system is fully unsaturated, i.e., it contains a cyclic, delocalized (4n+2) ⁇ - electron system in accordance with the H ⁇ ckel theory.
- aryl radicals include, but are not limited to, phenyl and naphthyl .
- aryl is meant to include both aryl and “substituted aryl, " which refers to an aryl radical in which one or more hydrogen atoms are replaced by one or more substituents independently selected from: acyl , alkoxy, aryl, cyano, cycloalkyl, halo, hydroxy1 , nitro, -OC(O)-R 11 , -N(R U ) 2 , -C(O)OR 11 , -C(O)N(R U ) 2 , -N(R n )C(O)OR n , -N(R U )C(O)R U , -N(R u )S(O) t R u (where t is 1 or 2), -S(O) 1 OR 11 (where t is 1 or 2),
- Halo refers to fluoro, chloro, bromo and iodo.
- the active form of the compounds is not suitable for I.V. injection due to the low solubility thereof in an aqueous medium ⁇ e.g., saline or water).
- the prodrug forms described herein are suitable for I.V. injection due to their improved solubility in the aqueous medium.
- a phosphate prodrug is used; and when one or two Na atoms were introduced at the phosphate moiety, the solubility is further improved.
- sodium hydroxide is added (e.g., dropwise) to the phosphate compound at a specific value of pH to perform substitution with one or two protons of the the phosphate moiety with sodium ions.
- a further embodiment provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of Chemical Formula (I) and a pharmaceutically acceptable excipient.
- the compounds or compositions of the present invention may be used in treating AML as described in detail below.
- the pharmaceutical composition of the present invention is formulated to be compatible with its intended route of administration.
- routes of administration include parenteral , e.g. , intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal , and rectal administration.
- Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose.
- a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents
- antibacterial agents such as benzyl alcohol or methyl parabens
- antioxidants such as ascorbic acid or sodium bisulfite
- chelating agents such as ethylene
- the pharmaceutically acceptable excipient is suitable for use in I.V. administration, such as I.V. injection or infusion.
- Suitable carriers for I.V. administration include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, NJ) or phosphate buffered saline (PBS).
- the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
- oral compositions that generally include an inert diluent or an edible carrier are provided.
- compositions can be enclosed in gelatin capsules or compressed into tablets.
- compound described herein can be incorporated with excipients and used in the form of tablets, troches, or capsules.
- Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed.
- Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
- the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin! or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
- a binder such as microcrystalline cellulose, gum tragacanth or gelatin
- an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch
- a lubricant such as magnesium stearate or Sterotes
- a glidant such as colloidal silicon dioxide
- the present disclosure provides a method of treatment of diseases, particularly cancer, more particularly acute myeloid leukemia (AML) comprising administering to a cancer patient ⁇ e.g., a patient with AML) an effective amount of a compound of Chemical Formula (I) or a pharmaceutical composition comprising the same.
- AML acute myeloid leukemia
- Example 23 provides below demonstrates that exemplary compounds of the present disclosure are effective in treating AML in an animal model.
- Methods known in the art may be used to determine the effectiveness of a compound provided here in treating cancer, such as AML.
- the method described in Example 23 may be used for assessing the anticancer activity of a given compound.
- Additional exemplary methods for assessing the activity of a compound in treating AML include those described in Bishop et al., Blood 87: 1710-7, 1996; Bishop, Semin Oncol 24:57-69, 1997; and Estey, Oncology 16: 343- 52, 2002.
- the compounds of the present disclosure may be administered to a patient in need thereof via various routes, such as orally, topically, transdermal Iy, or parenteral Iy.
- the compounds or compositions thereof are administered parenterally.
- parenteral includes subcutaneous injections, intravenous, intramuscular, intracisternal injections, and intravenous infusions.
- the compounds or compositions are administered via injection, such as intravenous injections.
- Toxicity and therapeutic efficacy of compounds of the present disclosure can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population).
- the dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50.
- Compounds that exhibit large therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.
- the data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans.
- the dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity.
- In vitro cardiotoxicity of the compounds may be determined according to the method described in Example 24 below.
- the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
- the therapeutically effective dose can be estimated initially from cell culture assays.
- a dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture.
- IC50 i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms
- levels in plasma may be measured, for example, by high performance liquid chromatography.
- the effective dose depends on the type of disease, the composition used, the route of administration, the type of subject being treated, the physical characteristics of the specific subject under consideration for treatment, concurrent medication, and other factors that those skilled in the medical arts will recognize.
- a compound of the present disclosure may be administered via I.V. injection or infusion at an amount between 0.5 mg/kg and 500 mg/kg (e.g., 0.5 to 10 mg/kg, 10 to 100 mg/kg, about 100 to 500 mg/kg body weight) which can be administered as a single dose, daily, weekly, monthly, or at any appropriate interval.
- the disclosed compounds may be used in treating AML in a manner similar to that used for Ara-C.
- the present invention provides a method for manufacturing the reverse turn mimetics of the present invention on a mass scale.
- the method comprises the following sequential steps: introducing an acyl group into indole-7-carbaldehyde, preferably through Friedel-Crafts acylation to provide 3-acyl-indole-7-carbaldehyde; introducing an alkyl group and an aminoacetal group to 3-acyl-indole-7- carbaldehyde to provide a l-alkyl-3-acyl-indole derivative; amidating the l-alkyl-3-acyl-indole derivative with stereoselectivity with Cbz-Tyr(OtBu) (i.e., (S)-2-(benzyloxycarbonylamino)-3-(4-tert- butoxyphenyl)propanoic acid) and 2-(l-allyl-4-benzylsemicarbazido)acetic acid to provide a reaction
- 2-(l-allyl-4-benzylsemicarbazido)acetic acid may be prepared by the following sequential steps: adding TEA(triethylamine) to an ethylhydrazinoacetate solution to form a reaction solution; adding allyl bromide (e.g., dropwise) to the reaction solution; and adding benzyl isocyanate (e.g. , dropwise).
- R 3 is methyl
- Rb is -C(O)Rs
- Re is methyl or cyclopropyl
- reaction scheme is directed to novel reverse turn mimics, represented by Chemical Formula I.
- the compounds according to the present invention are based on a framework of pyrazino-triazinone, with four different functional groups attached thereto. Due to the two chiral centers thereof, the compounds must be synthesized stereoselective ⁇ .
- acyl group is introduced into the indole-7-carbaldehyde of AAl through Friedel-Crafts acylation, followed by the introduction of alkyl and aminoacetal groups.
- AA2 the chiral compound
- the resulting intermediate is subjected to stereoselective amidation with PivCI (Pivaloylchloride) and iBCF (isobutylchloroformate) to afford AA3.
- AA3 is cyclized with formic acid to obtain AA4, followed by phosphorylization, introduction of salt (addition of Na to phosphate using 0.5N NaOH) and lyophilization to synthesize highly pure pyrazino-triazone compounds, AA5.
- phosphorylization introduction of salt (addition of Na to phosphate using 0.5N NaOH) and lyophilization to synthesize highly pure pyrazino-triazone compounds, AA5.
- the manufacturing method of the present invention is illustrated in detail as follows.
- the MC (dichloromethane) layer thus obtained was dehydrated with 269 g of ⁇ SO 4 , filtered, and then concentrated in a vacuum.
- the concentrate is crystallized with 134 ml of EA (ethylacetate) and 269 ml of hexane, followed by filtration.
- the solid thus obtained was slurried in 134 ml of EA (ethylacetate), filtered at O 2 C and dried in a vacuum to produce 40 g of S3 as a white solid (yield 35%).
- the organic layer thus formed was washed with 898 ml of a 5% aqueous citric acid solution and 898ml of a 5% aqueous NaHC03 solution, dehydrated with Na2S04 (sodium sulfate), and concentrated to afford Q7 as a concentrated residue.
- the concentrate was dissolved in MC (dichloromethane) to which 1 ml of TFA (trifluoroacetic acid) was then dropwise added, followed by stirring at room temperature. After the completion of the reaction, the reaction mixture was washed with 10 ml of a 5% aqueous NaHCO 3 solution and dehydrated with Na 2 SO 4 (sodium sulfate) to give Q3 as a concentrated residue.
- TFA trifluoroacetic acid
- the compounds were prepared in the form of prodrugs to improve the solubility thereof.
- Phosphate may be introduced as a possible prodrug substituent which can exist as in either monosodiumphosphate or disodiumphosphate form.
- This prodrug was prepared by adding sodium hydroxide to P2, which was synthesized according to Example 9. Both monosodium and disodium forms of the prodrug show a solubility of up to 400 mg/ml . Both forms have advantageous properties as a composition for I.V. injection in that a monosodium form has pH 4.45 and a disodium form has pH of 7.62.
- FIG. 1 graphically shows changes in pH and potential when 0.5N NaOH is added dropwise to the compound of the present invention.
- the horizontal axis represents the added amounts of sodium hydroxide.
- the first and second points of inflection correspond to the time of production of monosodium and disodium forms, respectively.
- AML Acute Myeloid Leukemia
- Animal Model Test materials were prepared in the form of prodrugs to increase the solubility of compounds of interest.
- a phosphate functional group which may be either a monosodium or disodium form was introduced as a prodrug substituent.
- the human AML cell line, MV4-11 was purchased (ATCC, U.S.A.) and cultured at 37 ⁇ C under a 5% CO2 condition in Iscove' s Modified Dulbecco' s Medium (GIBCO, cat# 21056) supplemented with 10% fetal bovine serum (GIBCO, cat# 25030-081).
- Female Balb/C nude mice (OrientBio, Sungnam-city, Korea), 5-6 weeks old, were acclimated to the breeding room.
- mice Using a sterilized syringe, a mixture of 1:1 of MV4-11 cells : matrigel (v/v) was implanted in an amount of 5xl0 6 /mouse beneath the axilla of each of the mice.
- the test materials were dissolved in physiological saline and intravenously injected at a dose of 10 ml/kg once a day and five times per week for two weeks (administration days of test materials, D1-D5, D8-D12). For a control, only physiological saline was used.
- the tumor size was determined as calculated by the following equation: Long Axis x Short Axis x Short Axis/2.
- the Long and Short Axes of the tumor were measured in length using a digital caliper (Mitsutoyo, Japan).
- the anticancer activity of the test materials was numerated according to the following equation.
- Tumor growth Inhibition Rates of tumor growth of the test materials are summarized in Table 2, below.
- Test results exhibit that all test compounds have inhibitory activity against tumor growth.
- tumor inhibition rates were measured to range from 70% to regression (>100%).
- Ara-C a widely used drug for AML, was found to have a tumor inhibition rate of 66%.
- HEK293 was transfected with hERG (human Ether-a-go-go Related Gene) cDNA for 48 hrs using Lipofectamine 2000 (Invitrogen, USA).
- the transfected HEK293 cells were cultured in Modified Dulbecco' s Medium (MEM, Gibco, 1 L) supplemented with 10% FBS, sodium pyruvate (10 ml), penicillin/streptomycin (10 ml) and Zeocin (100 ⁇ g/ml, Invitrogen) at 37 2 C under 5% CO 2 .
- MEM Modified Dulbecco' s Medium
- FBS sodium pyruvate
- penicillin/streptomycin 10 ml
- Zeocin 100 ⁇ g/ml, Invitrogen
- the membrane potential was depolarized from -80 mV to +20 mV for 1,000 ms in a whole-cell patch clamp mode and then repolarized to -40 mV for 1,000 ms, during which the tail current of outward hERG K+ currents was recorded.
- concentrations of the compounds that are required for 50% inhibition of the current were represented as IC50.
- the risk of cardiotoxicity has been raised in many drugs. Some of them were withdrawn from the market because they caused a sudden death due to the cardiotoxicity thereof.
- the cardiotoxicity of drugs is associated with the extension of QT intervals on electrocardiograms. Particularly, most of the drugs extending QT intervals are known to inhibit IKr channels (Bernard Fermini and Anthony A. Fossa, Nature Reviews Drug Discovery, 2003, 2, 439-447).
- the hERG channel shows the most important effect on cardiotoxicity among IKr channels.
- the risk of cardiotoxicity was evaluated using human hERG channel-expressing mammal cells, which are internationally recognized as a system (ICH guideline, S7B, Step4, 12, May, 2005).
- a drug is evaluated as having a low cardiotoxicity risk when IC50 thereof is 10 ⁇ M or higher. In this assay, most test compounds were found to overpass this criterion. Having higher IC50, compound Al was evaluated to be safer than compound A, and compounds Bl, B2 and B3 than compound B.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI1014574-5A BRPI1014574A2 (en) | 2009-04-15 | 2010-04-14 | Unpublished compounds of reverse link mimics, method for manufacturing them and use of these |
EP10764651A EP2419430A4 (en) | 2009-04-15 | 2010-04-14 | Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof |
MX2011010765A MX340424B (en) | 2009-04-15 | 2010-04-14 | Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof. |
AU2010237633A AU2010237633B2 (en) | 2009-04-15 | 2010-04-14 | Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof |
JP2012505818A JP5657642B2 (en) | 2009-04-15 | 2010-04-14 | Novel compounds of reverse turn analogues and their production and use |
CN201080026459.9A CN102459271B (en) | 2009-04-15 | 2010-04-14 | Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof |
RU2011146146/04A RU2515983C2 (en) | 2009-04-15 | 2010-04-14 | Novel compounds of reverse turn mimetics, method of their manufacturing and application |
CA2758904A CA2758904C (en) | 2009-04-15 | 2010-04-14 | Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof |
SG2011072147A SG175045A1 (en) | 2009-04-15 | 2010-04-14 | Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof |
KR1020117026683A KR101692921B1 (en) | 2009-04-15 | 2010-04-14 | Novel compounds of reveres turn mimetics, the process of preparation and the use thereof |
ZA2011/07357A ZA201107357B (en) | 2009-04-15 | 2011-10-07 | Novel compounds of reverse-turn mimetics, method for manufacturing the same and use therof |
IL215732A IL215732A (en) | 2009-04-15 | 2011-10-11 | Compounds of reverse-turn mimetics, method for manufacturing the same and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2009-0032937 | 2009-04-15 | ||
KR20090032937 | 2009-04-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010120112A2 true WO2010120112A2 (en) | 2010-10-21 |
WO2010120112A3 WO2010120112A3 (en) | 2011-03-31 |
Family
ID=42981437
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2010/002306 WO2010120112A2 (en) | 2009-04-15 | 2010-04-14 | Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof |
Country Status (14)
Country | Link |
---|---|
US (1) | US20100267672A1 (en) |
EP (1) | EP2419430A4 (en) |
JP (1) | JP5657642B2 (en) |
KR (1) | KR101692921B1 (en) |
CN (1) | CN102459271B (en) |
AU (1) | AU2010237633B2 (en) |
BR (1) | BRPI1014574A2 (en) |
CA (1) | CA2758904C (en) |
IL (1) | IL215732A (en) |
MX (1) | MX340424B (en) |
RU (1) | RU2515983C2 (en) |
SG (1) | SG175045A1 (en) |
WO (1) | WO2010120112A2 (en) |
ZA (1) | ZA201107357B (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011096440A1 (en) | 2010-02-03 | 2011-08-11 | PRISM BioLab株式会社 | Compound capable of binding to naturally occurring denatured protein, and method for screening for the compound |
WO2013022257A2 (en) | 2011-08-09 | 2013-02-14 | 제이더블유중외제약 주식회사 | Composition for preventing and treating non-small cell lung cancer, containing pyrazino-triazine derivatives |
WO2013032184A2 (en) * | 2011-08-26 | 2013-03-07 | 제이더블유중외제약 주식회사 | Composition comprising pyrazino-triazine derivatives |
CN103209982A (en) * | 2010-10-14 | 2013-07-17 | Jw制药公司 | Novel compound of a reverse-turn mimetic and a production method and use therefor |
JP2014509298A (en) * | 2011-02-25 | 2014-04-17 | 株式会社PRISM Pharma | Alpha helix mimetics and related methods |
US9353119B2 (en) | 2011-08-09 | 2016-05-31 | Jw Pharmaceutical Corporation | Composition for preventing and treating non-small cell lung cancer, containing pyrazino-triazine derivatives |
RU2669805C2 (en) * | 2013-12-25 | 2018-10-16 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | (6s,9as)-n-benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl)azethydin-1-yl]pyridine-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1h-pyrasino[2,1-c][1,2,4]triazine-1-carboxamide compound |
US10259817B2 (en) | 2015-06-23 | 2019-04-16 | Eisai R&D Management Co., Ltd. | Crystal (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide |
US11369623B2 (en) | 2015-06-16 | 2022-06-28 | Prism Pharma Co., Ltd. | Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201601767YA (en) * | 2013-09-11 | 2016-04-28 | Prism Pharma Co Ltd | Method of producing pyrazino[2,1-c][1,2,4]triazine compound |
WO2015074081A1 (en) * | 2013-11-18 | 2015-05-21 | Bair Kenneth W | Benzopiperazine compositions as bet bromodomain inhibitors |
BR122019007990B1 (en) | 2013-11-18 | 2021-05-04 | Forma Therapeutics, Inc | COMPOUND, AND, PHARMACEUTICAL COMPOSITION |
WO2019055877A1 (en) | 2017-09-15 | 2019-03-21 | Forma Therapeutics, Inc. | Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors |
IL279734B1 (en) | 2018-06-29 | 2024-07-01 | Forma Therapeutics Inc | Inhibiting creb binding protein (cbp) |
KR20210153908A (en) * | 2020-06-11 | 2021-12-20 | 제이더블유중외제약 주식회사 | Composition for Treating COVID-19 |
KR20220000460A (en) | 2020-06-26 | 2022-01-04 | 제이더블유중외제약 주식회사 | Composition for Treating Pulmonary Fibrosis |
US11801243B2 (en) | 2020-09-23 | 2023-10-31 | Forma Therapeutics, Inc. | Bromodomain inhibitors for androgen receptor-driven cancers |
US11795168B2 (en) | 2020-09-23 | 2023-10-24 | Forma Therapeutics, Inc. | Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP) |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US559184A (en) * | 1896-04-28 | Eli marshall | ||
WO1992013878A2 (en) * | 1991-02-07 | 1992-08-20 | Board Of Trustees Of The University Of Illinois | Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same |
US5475085A (en) * | 1991-02-07 | 1995-12-12 | Molecumetics, Ltd. | Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same |
JPH07509723A (en) | 1992-08-06 | 1995-10-26 | モレキュメティクス,リミティド | Conformationally constrained mimetics of inverted turns and peptides containing the former |
US5446128A (en) * | 1993-06-18 | 1995-08-29 | The Board Of Trustees Of The University Of Illinois | Alpha-helix mimetics and methods relating thereto |
US5693325A (en) * | 1994-03-15 | 1997-12-02 | Molecumetics, Ltd. | Peptide vaccines and methods relating thereto |
US6245764B1 (en) * | 1995-03-24 | 2001-06-12 | Molecumetics Ltd. | β-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins |
US6020331A (en) * | 1995-03-24 | 2000-02-01 | Molecumetics, Ltd. | β-sheet mimetics and use thereof as protease inhibitors |
US5929237A (en) * | 1995-10-27 | 1999-07-27 | Molecumetics Ltd. | Reverse-turn mimetics and methods relating thereto |
US6013458A (en) * | 1995-10-27 | 2000-01-11 | Molecumetics, Ltd. | Reverse-turn mimetics and methods relating thereto |
US6184223B1 (en) * | 1995-10-27 | 2001-02-06 | Molecumetics Ltd. | Reverse-turn mimetics and methods relating thereto |
US5840833A (en) * | 1995-10-27 | 1998-11-24 | Molecumetics, Ltd | Alpha-helix mimetics and methods relating thereto |
US6117896A (en) * | 1997-02-10 | 2000-09-12 | Molecumetics Ltd. | Methods for regulating transcription factors |
US6451972B1 (en) * | 1998-11-16 | 2002-09-17 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors |
US7192494B2 (en) * | 1999-03-05 | 2007-03-20 | Applied Materials, Inc. | Method and apparatus for annealing copper films |
US6294525B1 (en) * | 1999-09-01 | 2001-09-25 | Molecumetics Ltd. | Reverse-turn mimetics and methods relating thereto |
US6872825B2 (en) * | 1999-12-21 | 2005-03-29 | The Procter & Gamble Company | Peptide β-turn mimetic compounds and processes for making them |
DE10005631A1 (en) * | 2000-02-09 | 2001-08-23 | Max Planck Gesellschaft | Arginine Mimetics as Factor X¶a¶ Inhibitors |
US7232822B2 (en) * | 2001-10-12 | 2007-06-19 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
US7566711B2 (en) * | 2001-10-12 | 2009-07-28 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
US20040072831A1 (en) * | 2001-10-12 | 2004-04-15 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
US7671054B1 (en) * | 2001-10-12 | 2010-03-02 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
US8080657B2 (en) * | 2001-10-12 | 2011-12-20 | Choongwae Pharma Corporation | Compounds of reverse turn mimetics and the use thereof |
ES2310215T3 (en) * | 2001-10-12 | 2009-01-01 | Choongwae Pharma Corporation | MIMETIC STRUCTURES OF REVERSE TURN AND RELATED METHOD. |
US7576084B2 (en) * | 2001-10-12 | 2009-08-18 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
US6762185B1 (en) * | 2002-03-01 | 2004-07-13 | Choongwae Pharma Corporation | Compounds useful for treatment of cancer, compositions containing the same, and methods of their use |
RU2383547C2 (en) * | 2003-08-28 | 2010-03-10 | Чоонгвае Фарма Корпорейшн | Modulation of beta-catenin/tcf-activated transcription |
US7563825B1 (en) * | 2005-03-18 | 2009-07-21 | Choongwae Pharma Corporation | Modulation of beta-catenin coactivator interactions to effect stem cell growth or differentiation |
KR101486490B1 (en) * | 2005-11-08 | 2015-01-27 | 제이더블유중외제약 주식회사 | α-HELIX MIMETICS AND METHOD RELATING TO THE TREATMENT OF CANCER STEM CELLS |
JP2009538903A (en) * | 2006-05-30 | 2009-11-12 | チュンウェ ファーマ コーポレーション | Composition for inducing or suppressing stem cell differentiation |
-
2010
- 2010-04-14 WO PCT/KR2010/002306 patent/WO2010120112A2/en active Application Filing
- 2010-04-14 AU AU2010237633A patent/AU2010237633B2/en active Active
- 2010-04-14 BR BRPI1014574-5A patent/BRPI1014574A2/en active IP Right Grant
- 2010-04-14 RU RU2011146146/04A patent/RU2515983C2/en active
- 2010-04-14 CN CN201080026459.9A patent/CN102459271B/en active Active
- 2010-04-14 MX MX2011010765A patent/MX340424B/en active IP Right Grant
- 2010-04-14 KR KR1020117026683A patent/KR101692921B1/en active IP Right Grant
- 2010-04-14 JP JP2012505818A patent/JP5657642B2/en active Active
- 2010-04-14 CA CA2758904A patent/CA2758904C/en active Active
- 2010-04-14 US US12/759,854 patent/US20100267672A1/en not_active Abandoned
- 2010-04-14 EP EP10764651A patent/EP2419430A4/en not_active Withdrawn
- 2010-04-14 SG SG2011072147A patent/SG175045A1/en unknown
-
2011
- 2011-10-07 ZA ZA2011/07357A patent/ZA201107357B/en unknown
- 2011-10-11 IL IL215732A patent/IL215732A/en active IP Right Grant
Non-Patent Citations (1)
Title |
---|
See references of EP2419430A4 * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011096440A1 (en) | 2010-02-03 | 2011-08-11 | PRISM BioLab株式会社 | Compound capable of binding to naturally occurring denatured protein, and method for screening for the compound |
EP2628741A4 (en) * | 2010-10-14 | 2013-08-21 | Jw Pharmaceutical Corp | Novel compound of a reverse-turn mimetic and a production method and use therefor |
US8940739B2 (en) | 2010-10-14 | 2015-01-27 | Jw Pharmaceutical Corporation | Compound of a reverse-turn mimetic and a production method and use therefor |
EP2628741A2 (en) * | 2010-10-14 | 2013-08-21 | JW Pharmaceutical Corporation | Novel compound of a reverse-turn mimetic and a production method and use therefor |
CN103209982A (en) * | 2010-10-14 | 2013-07-17 | Jw制药公司 | Novel compound of a reverse-turn mimetic and a production method and use therefor |
JP2014509298A (en) * | 2011-02-25 | 2014-04-17 | 株式会社PRISM Pharma | Alpha helix mimetics and related methods |
WO2013022257A3 (en) * | 2011-08-09 | 2013-06-13 | 제이더블유중외제약 주식회사 | Composition for preventing and treating non-small cell lung cancer, containing pyrazino-triazine derivatives |
CN103930113A (en) * | 2011-08-09 | 2014-07-16 | Jw制药公司 | Composition for preventing and treating non-small cell lung cancer, containing pyrazino-triazine derivatives |
JP2014521718A (en) * | 2011-08-09 | 2014-08-28 | ジェイダブリュ ファーマセウティカル コーポレーション | Composition for prevention and treatment of non-small cell lung cancer comprising pyrazino-triazine derivative |
WO2013022257A2 (en) | 2011-08-09 | 2013-02-14 | 제이더블유중외제약 주식회사 | Composition for preventing and treating non-small cell lung cancer, containing pyrazino-triazine derivatives |
US9353119B2 (en) | 2011-08-09 | 2016-05-31 | Jw Pharmaceutical Corporation | Composition for preventing and treating non-small cell lung cancer, containing pyrazino-triazine derivatives |
CN103930113B (en) * | 2011-08-09 | 2016-08-17 | Jw制药公司 | For preventing and treat the compositions comprising pyrazine pyrrolotriazine derivatives of nonsmall-cell lung cancer |
TWI557128B (en) * | 2011-08-09 | 2016-11-11 | Jw製藥公司 | Use of a composition for the manufacture of a medicament for preventing or treating nsclc |
WO2013032184A3 (en) * | 2011-08-26 | 2013-04-25 | 제이더블유중외제약 주식회사 | Composition comprising pyrazino-triazine derivatives |
WO2013032184A2 (en) * | 2011-08-26 | 2013-03-07 | 제이더블유중외제약 주식회사 | Composition comprising pyrazino-triazine derivatives |
RU2669805C2 (en) * | 2013-12-25 | 2018-10-16 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | (6s,9as)-n-benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl)azethydin-1-yl]pyridine-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1h-pyrasino[2,1-c][1,2,4]triazine-1-carboxamide compound |
US11369623B2 (en) | 2015-06-16 | 2022-06-28 | Prism Pharma Co., Ltd. | Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor |
US10259817B2 (en) | 2015-06-23 | 2019-04-16 | Eisai R&D Management Co., Ltd. | Crystal (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide |
Also Published As
Publication number | Publication date |
---|---|
BRPI1014574A2 (en) | 2015-08-25 |
CA2758904C (en) | 2017-04-04 |
JP5657642B2 (en) | 2015-01-21 |
MX340424B (en) | 2016-07-08 |
RU2011146146A (en) | 2013-05-20 |
EP2419430A4 (en) | 2012-10-31 |
MX2011010765A (en) | 2012-02-08 |
US20100267672A1 (en) | 2010-10-21 |
AU2010237633B2 (en) | 2015-09-17 |
KR20120028877A (en) | 2012-03-23 |
CA2758904A1 (en) | 2010-10-21 |
IL215732A0 (en) | 2012-01-31 |
IL215732A (en) | 2014-08-31 |
EP2419430A2 (en) | 2012-02-22 |
KR101692921B1 (en) | 2017-01-05 |
SG175045A1 (en) | 2011-11-28 |
WO2010120112A3 (en) | 2011-03-31 |
JP2012524061A (en) | 2012-10-11 |
CN102459271A (en) | 2012-05-16 |
CN102459271B (en) | 2014-07-02 |
RU2515983C2 (en) | 2014-05-20 |
AU2010237633A1 (en) | 2011-10-27 |
ZA201107357B (en) | 2012-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2010237633B2 (en) | Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof | |
RU2409579C2 (en) | Compositions and methods of treating cancer | |
EP2829545B1 (en) | New phosphate derivatives, method of preparing same and pharmaceutical compositions containing them | |
ES2461967T3 (en) | Pyrrolo [2,3-d] pyrimidine compounds | |
EP3919483A1 (en) | Benzopyridone heterocyclic compound and use thereof | |
EP3816163A1 (en) | Cell necrosis inhibitor, preparation method therefor and use thereof | |
CN102827170A (en) | Active treatment compositions and use method thereof | |
EP1793823B1 (en) | Phosphate containing prodrugs of sulfonyl hydrazines as hypoxia-selective antineoplastic agents | |
JP2010514772A (en) | Cyclitol and its derivatives and therapeutic uses thereof | |
US7960420B2 (en) | Diazonamide analogs with improved solubility | |
JP2019523259A (en) | Pantethein derivatives for the treatment of neurological disorders | |
FI90982B (en) | Analogous process for the preparation of therapeutically useful mitomycin phosphate derivatives | |
KR101672975B1 (en) | Cyclic phosphopeptide compounds as allosteric plk1-pbd inhibitor | |
WO2023142803A1 (en) | Antiviral compound and use thereof | |
BRPI1014574B1 (en) | "Imitation-binding compounds, Pharmaceutical composition, Understanding them, Method for manufacturing and preparing the same, and Use of the pharmaceutical composition dialect" | |
OA16962A (en) | New phosphate derivatives, their preparation process and the pharmaceutical compositions which contain them. | |
EP2523948A1 (en) | Pro-drugs of (e) -7- (3- (2-amino-1-fluoroethylidene) piperidin-1-yl) -1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080026459.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10764651 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 215732 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2011/010765 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012505818 Country of ref document: JP Ref document number: 2758904 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 596006 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2010237633 Country of ref document: AU Date of ref document: 20100414 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20117026683 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 8807/DELNP/2011 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2011146146 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010764651 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI1014574 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: PI1014574 Country of ref document: BR Kind code of ref document: A2 Effective date: 20111014 |